🇺🇸 alpha-1-Proteinase Inhibitor in United States

908 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 908

Most-reported reactions

1. Pneumonia — 143 reports (15.75%)
2. Dyspnoea — 137 reports (15.09%)
3. Product Dose Omission Issue — 132 reports (14.54%)
4. Covid-19 — 90 reports (9.91%)
5. Death — 83 reports (9.14%)
6. Cough — 81 reports (8.92%)
7. Fall — 65 reports (7.16%)
8. Fatigue — 62 reports (6.83%)
9. Respiratory Tract Infection — 60 reports (6.61%)
10. Sinusitis — 55 reports (6.06%)

Source database →

Frequently asked questions

Is alpha-1-Proteinase Inhibitor approved in United States?

alpha-1-Proteinase Inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for alpha-1-Proteinase Inhibitor in United States?

Institute for Human Genetics and Biochemistry is the originator. The local marketing authorisation holder may differ — check the official source linked above.